Search Results

NovellusDx (or the “Company”), a clinical-stage biotechnology company focused on precision oncology, today announced that it is establishing Fore Biotherapeutics U.S. as its operating company in the United States to reflect its evolved biotech business model focused on matching patients with unaddressed tumor mutations with the right medicines in the clinic.

NovellusDx, Ltd. and Primetech Co., Ltd. announce that Primetech will provide NovellusDx’ functional genomics assay “FACT – Functional Annotation for Cancer Treatment” as an exclusive dealer in Japan for the pre-clinical market with sales, marketing and research support / technical support in Japan.

The launch of Fore Biotherapeutics in the U.S. reflects an evolved biotech business model focused on matching patients with unaddressed tumor mutations with the right oncology medicines in the clinic, the company said.

Chardan, a global investment bank, announced today that the firm acted as exclusive financial advisor to NovellusDx., a leader in functional genomics, for the firm’s agreement to merge with a newly formed Israeli subsidiary of Cancer Genetics, Inc.. (NASDAQ: CGIX).

NovellusDx announced it has completed an equity financing of $6 million.

Centre Léon-Bérard and the biotechnology company NovellusDx are collaborating on a retrospective analysis of two study arms of the MOST trial.